Harrow (NASDAQ:HROW) Price Target Raised to $64.00

Harrow (NASDAQ:HROW) had its price target hoisted by Craig Hallum from $54.00 to $64.00 in a research note released on Tuesday morning, Marketbeat.com reports. The firm currently has a buy rating on the stock.

HROW has been the topic of a number of other research reports. HC Wainwright boosted their target price on shares of Harrow from $60.00 to $64.00 and gave the stock a “buy” rating in a research report on Wednesday, August 13th. Zacks Research downgraded shares of Harrow from a “strong-buy” rating to a “hold” rating in a report on Friday, September 12th. William Blair began coverage on shares of Harrow in a research report on Tuesday, June 10th. They set an “outperform” rating for the company. BTIG Research increased their target price on shares of Harrow from $62.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, August 14th. Finally, Cantor Fitzgerald initiated coverage on Harrow in a research note on Friday, July 11th. They set an “overweight” rating and a $76.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $65.33.

Harrow Trading Down 3.6%

Harrow stock opened at $46.15 on Tuesday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.58 and a current ratio of 0.62. The business’s 50-day simple moving average is $38.25 and its 200-day simple moving average is $31.21. The firm has a market capitalization of $1.71 billion, a PE ratio of -184.60 and a beta of 0.33. Harrow has a 52 week low of $20.85 and a 52 week high of $59.23.

Harrow (NASDAQ:HROW) last announced its earnings results on Monday, August 11th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.23. The firm had revenue of $63.74 million during the quarter, compared to the consensus estimate of $64.23 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Harrow has set its FY 2025 guidance at EPS. Equities research analysts forecast that Harrow will post -0.53 earnings per share for the current year.

Institutional Investors Weigh In On Harrow

Large investors have recently modified their holdings of the stock. Osaic Holdings Inc. raised its holdings in shares of Harrow by 10.3% in the 2nd quarter. Osaic Holdings Inc. now owns 24,031 shares of the company’s stock worth $734,000 after buying an additional 2,249 shares in the last quarter. Tower Research Capital LLC TRC grew its position in Harrow by 345.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company’s stock valued at $103,000 after acquiring an additional 2,615 shares during the period. Engineers Gate Manager LP grew its position in Harrow by 194.7% in the second quarter. Engineers Gate Manager LP now owns 35,565 shares of the company’s stock valued at $1,086,000 after acquiring an additional 23,495 shares during the period. Bank of America Corp DE raised its stake in Harrow by 266.8% during the second quarter. Bank of America Corp DE now owns 213,448 shares of the company’s stock worth $6,519,000 after acquiring an additional 155,258 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Harrow during the second quarter valued at $48,000. 72.76% of the stock is currently owned by institutional investors.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.